{"id":3714,"date":"2021-11-11T13:52:40","date_gmt":"2021-11-11T12:52:40","guid":{"rendered":"https:\/\/www.modag.net\/modag-neuroscience-solutions\/"},"modified":"2026-07-15T10:44:42","modified_gmt":"2026-07-15T08:44:42","slug":"modag-neuroscience-solutions","status":"publish","type":"page","link":"https:\/\/www.modag.net\/en\/","title":{"rendered":"Modag Neuroscience Solutions"},"content":{"rendered":"

\"Patients<\/a><\/span><\/div>

Patients & relatives<\/a><\/p><\/a><\/h3><\/div>

Find out more about our innovative therapeutic approaches and ongoing clinical studies on neurodegenerative diseases – from disease information to research results.<\/p>\n<\/div>

Information for those affected
<\/span><\/a><\/div><\/div><\/div>
\"Patients<\/a><\/span><\/div>

Research<\/a><\/h3><\/div>

Find out more about our research into therapeutics, in particular our oligomer modulators, as well as our clinical studies and scientific publications.<\/p>\n<\/div>

State of research
<\/span><\/a><\/div><\/div><\/div>
\"Patients<\/a><\/span><\/div>

Diagnostics<\/a><\/a><\/h3><\/div>

Find out more about our innovative diagnostic procedures such as PET tracers and SAA (Seed Amplification Assay) for the early detection of neurodegenerative diseases. We will soon be using the SAA test PD DETECT in our newly established single-use laboratory. <\/p>\n<\/div>

Get to know the diagnostics laboratory
<\/span><\/a><\/div><\/div><\/div><\/div><\/div>\n
<\/div>

Breakthrough instead of borders.<\/h4><\/div>

Our aim is to give<\/span> patients with neurodegenerative diseases new hope<\/span> and <\/span>create opportunities to slow down, stop or even reverse<\/span> the progression of the disease.

<\/span><\/h3><\/div><\/div><\/div><\/div><\/div>
\"Ehepaar\"<\/span><\/div><\/div><\/div>

Neurodegenerative diseases<\/span> such as Parkinson’s disease and multiple system atrophy (MSA) affect millions of people<\/span> worldwide and no cure is yet available.<\/h3><\/div>
<\/div>

We want to change that. That’s why we give our all every day.<\/h4><\/div><\/div><\/div><\/div><\/div>

Facts on<\/span> Parkinson’s disease and MSA
<\/span><\/span><\/h2><\/div><\/div><\/div>
<\/i>

> 10 million<\/h3><\/div>

Approximately 10 million people worldwide are affected by Parkinson’s disease. After Alzheimer’s disease, Parkinson’s is the most common neurodegenerative disease and the most common movement disorder. <\/p>\n<\/div><\/div><\/div>

<\/i>

Frequency<\/h3><\/div>

MSA is a rarer disease (4 to 5 cases per 100,000 inhabitants), but progresses much faster than Parkinson’s disease.<\/p>\n<\/div><\/div><\/div>

<\/i>

Distribution<\/h3><\/div>

MSA affects men and women equally often, while Parkinson’s disease tends to be diagnosed more frequently in men.<\/p>\n<\/div><\/div><\/div>

<\/i>

Age<\/h3><\/div>

The age at which MSA is diagnosed is usually between the ages of 40 and 60.
The average age at which Parkinson’s disease is diagnosed is between the ages of 50 and 80.<\/p>\n<\/div><\/div><\/div>

<\/i>

Life expectancy<\/h3><\/div>

The average life expectancy after a diagnosis of Parkinson’s disease is around 10 to 20 years, and only around 6 years for MSA, which underlines the urgency of new therapeutic approaches.<\/p>\n<\/div><\/div><\/div><\/div><\/div>

+++ Phase 1 study successfully completed. +++ Phase 2 clinical trial with 200 study participants has started\u00a0 \u00a0<\/span>+++ Phase 1 study successfully completed. +++ Phase 2 clinical trial with 200 study participants has started\u00a0 \u00a0<\/span><\/h4><\/div><\/div><\/div><\/div><\/div>
\"Paar<\/span><\/div><\/div><\/div>

MODAG <\/span> is<\/span><\/span> developing pioneering therapeutics from the small molecule drug class<\/span><\/span> that can specifically dissolve pathological protein aggregates and have the potential to slow down, stop or even reverse the course of the disease.<\/h3><\/div><\/div><\/div><\/div><\/div>
<\/div>

MODAG: pioneer for transformative therapies in neurology.<\/span><\/span> The breakthrough came with the identification of emrusolmin (anle138b) – a promising oligomer modulator.<\/span><\/h3><\/div>

This patent-protected molecule became a pioneer in our Parkinson’s and MSA research and brought groundbreaking innovations in neurology.<\/p>\n<\/div>

Learn more<\/span><\/a><\/div><\/div><\/div><\/div><\/div>

Hope for the future. Pioneering therapies for neurodegenerative diseases.<\/span><\/span><\/h2><\/div>

At MODAG, we are passionate about developing breakthrough therapies for neurodegenerative diseases. Emrusolmin (anle138b) aims to stop the progression of the disease by harmful alpha-synuclein deposits<\/span> are dissolved.<\/p>\n<\/div>